Liver transplantation for hepatocellular carcinoma

Czech version

Authors: P. Taimr
Authors‘ workplace: Klinika hepatogastroenterologie, Institut klinické a experimentální medicíny, Praha
Published in: Gastroent Hepatol 2024; 78(2): 123-128
Category: Hepatology
doi: https://doi.org/10.48095/ccgh2024123

Overview

The number of liver transplants for the indication of hepatocellular carcinoma is increasing. We consider the so-called Milan criteria, based on the number and size of the tumour, to be the basic indication framework. However, the original criteria are too restrictive – they prevent access to transplantation for a number of patients who would otherwise be suitable candidates for transplantation. There is therefore an effort to somehow expand these criteria. Decision-making is also burdened by a possible error in imaging – our knowledge of the dimensions and number of nodules is not accurate before transplantation. Later, factors reflecting the biological properties of the tumour were added and it was possible to select patients for transplantation with greater precision. Examples here include the use of alpha-fetoprotein, histological grading, microinvasion into vessels, etc. Also, the response of the tumour to treatment before transplantation can be an important indicator – the effect of locoregional (RFA, MWA, TACE) or even systemic treatment. The importance of pre-transplant administration of immunomodulatory treatment is not yet known. In larger transplant centres, the concept of their own criteria, established on the basis of their own data unique to a given centre, is already beginning to be promoted. The advantage is that it reflects local and specific conditions of the centre.

Keywords:

liver transplantation – hepatocellular carcinoma – Milan criteria – IKEM criteria

Sources

1. White DL, Thrift AP, Kanwal F et al. Incidence of Hepatocellular Carcinoma in All 50 United States, from 2000 through 2012. Gastroenterology 2017; 152 (4): 812–820. doi: 10.1053/ j.gastro.2016.11.020.

2. Toniutto P, Fumolo E, Fornasiere E et al. Liver transplantation in patients with hepatocellular carcinoma beyond Milan criteria: A comprehensive review. J Clin Med 2021; 10 (17): 3932. doi: 10.3390/jcm10173932.

3. Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol 2020; 72 (2): 262–276. doi: 10.1016/j.jhep.2019.11.017.

4. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334 (11): 693–699. doi: 10.1056/NEJM199603143341104.

5. Costentin CE, Bababekov YJ, Zhu AX et al. Is It Time to Reconsider the Milan Criteria for Selecting Patients With Hepatocellular Carcinoma for Deceased-Donor Liver Transplantation? Hepatology 2019; 69 (3): 1324–1336. doi: 10.1002/hep.30278.

6. Zheng SS, Wu X, Wu J et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008; 85 (12): 1726–1732. doi: 10.1097/TP.0b013e31816b67e4.

7. Fan J, Zhou J, Xu Y et al. Indication of liver transplantation for hepatocellular carcinoma: Shanghai Fudan Criteria. Zhonghua Yi Xue Za Zhi 2006; 86 (18): 1227–1231.

8. Mazzaferro V, Llovet JM, Miceli R et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis. Lancet Oncol 2009; 10 (1): 35–43. doi: 10.1016/S1470-2045 (08) 70284-5.

9. Yao F, Ferrell L, Bass N et al. Liver transplantation for hepatocellular carcinoma: comparison of proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2022; 8 (9): 765–774. doi: 10.1053/jlts.2002.34892.

10. Yao F, Ferrell L, Bass N et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33 (6): 1394–1403. doi: 10.1053/jhep.2001.24563.

11. Harper A, Edwards E, Washburn W et al. An early look at the Organ Procurement and Transplantation Network explant pathology form data. Liver Transpl 2016; 22 (6): 757–764. doi: 10.1002/lt.24441.

12. Kierans AS, Song C, Gavlin A et al. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma. AJR Am J Roentgenol 2020; 215 (5): 1085–1092. doi: 10.2214/AJR.20.22772.

13. Lee S, Kim SS, Roh YH et al. Diagnostic Performance of CT/MRI Liver Imaging Reportingand Data System v2017 for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Liver Int 2020; 40 (6): 1488–1497. doi: 10.1111/liv.14424.

14. Zhang X, Li J, Shen F et al. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 2018; 33 (2): 347–354. doi: 10.1111/jgh. 13843.

15. Shah SA, Tan JC, McGilvray ID et al. Does microvascular invasion affect outcomes after liver transplantation for HCC? A histopathological analysis of 155 consecutive explants. J Gastrointest Surg 2007; 11 (4): 464–471. doi: 10.1007/s11605-006-0033-7.

16. Jonas S, Bechstein WO, Steinmuller T et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33 (5): 1080–1086. doi: 10.1053/jhep.2001.23561.

17. Shah SA, Tan JC, McGilvray ID et al. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation 2006; 81 (12): 1633–1639. doi: 10.1097/01.tp.0000226069.66819.7e.

18. Sweeney MJ, Ashmore J, Morris HP et al. Comparative Biochemistry Hepatomas. IV. Isotope Studies of Glucose and Fructose Metabolism in Liver Tumors of Different Growth Rates. Cancer Res 1963; 23: 995–1002.

19. Torizuka T, Tamaki N, Inokuma T et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995; 36 (10): 1811–1817.

20. Yaprak O, Acar S, Ertugrul G et al. Role of pre-transplant 18F-FDG PET/CT in predicting hepatocellular carcinoma recurrence after liver transplantation. World J Gastrointest Oncol 2018; 10 (10): 336–343. doi: 10.4251/wjgo.v10.i10.336.

21. Sapisochin G, Goldaracena N, Laurence JM et al. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. Hepatology 2016; 64 (6): 2077–2088. doi: 10.1002/hep.28643.

22. Toso C, Asthana S, Bigam DL et al. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology 2009; 49 (3): 832–838. doi: 10.1002/hep.22693.

23. Duvoux C, Roudot-Thoraval F, Decaens T et al. Liver transplantation for hepatocellular carcinoma: A model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012; 143 (3): 986–994. doi: 10.1053/j.gastro.2012.05.052.

24. Mazzaferro V, Sposito C, Zhou J et al. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. Gastroenterology 2018; 154 (1): 128–139. doi: 10.1053/j.gastro.2017.09.025.

25. Kaido T, Ogawa K, Mori A et al. Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma. Surgery 2013; 154 (5): 1053–1060. doi: 10.1016/j.surg.2013.04.056.

26. Soejima Y, Taketomi A, Yoshizumi T et al. Extended indication for living donor liver transplantation in patients with hepatocel- lular carcinoma. Transplantation 2007; 83 (7): 893–899. doi: 10.1097/01.tp.0000259015.46798.ec.

27. Lee JH, Cho Y, Kim HY et al. Serum Tumor Markers Provide Refined Prognostication in Selecting Liver Transplantation Candidate for Hepatocellular Carcinoma Patients Beyond the Milan Criteria. Ann Surg 2016; 263 (3): 842–850. doi: 10.1097/SLA.0000000000001578.

28. Chaiteerakij R, Zhang X, Addissie BD et al. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation. Liver Transplant 2015; 21 (5): 599–606. doi: 10.1002/lt.24117.

29. Clavien PA, Lesurtel M, Bossuyt PM et al. Recommendations for liver transplantation for hepatocellular carcinoma: An international consensus conference report. Lancet Oncol 2012; 13 (1): e11–e22. doi: 10.1016/S1470-2045 (11) 70175-9.

30. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69 (1): 182–236. doi: 10.1016/ j.jhep.2018.03.019.

31. Sonbol MB, Riaz IB, Naqvi SAA et al. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis. JAMA Oncol 2020; 6 (12): e204930. doi: 10.1001/jamaoncol.2020.4930.

32. Finn RS, Qin S, Ikeda M et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020; 382: 1894–1905. doi: 10.1056/NEJMoa1915745.

33. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30 (1): 52–60. doi: 10.1055/s-0030-1247132.

34. Heimbach JK, Kulik LM, Finn RS et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67 (1): 358–380. doi: 10.1002/hep.29086.

35. Mazzaferro V, Citterio D, Bhoori S et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): A randomised, controlled, phase 2b/3 trial. Lancet Oncol 2020; 21 (7): 947–956. doi: 10.1016/ S1470-2045 (20) 30224-2.

ORCID autora

P. Taimr 0000-0002-6272-4608b.

Doručeno/Submitted: 30. 3. 2024

Přijato/Accepted: 9. 4. 2024

doc. MUDr. Pavel Taimr, Ph.D.

vedoucí transplantační hepatolog

Klinika hepatogastroenterologie

Institut klinické a experimentální medicíny

Vídeňská 1958/9

140 21 Praha 4

pavel.taimr@ikem.cz